← 返回前沿论文

转移性胃癌图谱将铁死亡与疾病进展和免疫治疗反应联系起来

英文原题:Atlas of Metastatic Gastric Cancer Links Ferroptosis to Disease Progression and Immunotherapy Response.

PubMed 2024/08/02(内容时间) Gastroenterology Q1 · IF 29.7(JCR 2025)

研究概要

本研究代表了迄今为止最大的转移性GAC单细胞数据集。对GAC转移的分子和细胞动力学进行高分辨率映射,揭示了靶向铁死亡防御联合CAR-T 细胞疗法作为一种具有巨大潜在临床意义的新型治疗策略的理论依据。

研究思路结论见上方概要

胃腺癌(GAC)转移导致高发病率和死亡率。开发创新且有效的疗法需要全面了解晚期GAC的肿瘤和免疫生物学。然而,从晚期、未接受治疗的GAC患者中收集配对标本面临重大挑战,限制了当前研究的范围,目前研究主要集中于局限性肿瘤。这一空白阻碍了对GAC转移动态的深入认识。

我们对68对未经治疗的配对原发转移性肿瘤进行了深入的单细胞转录组和免疫分析,以描绘转移进展过程中癌细胞及其肿瘤微环境的变化。为验证我们的观察结果,我们利用细胞系以及多种患者来源异种移植模型和新型GAC小鼠模型,在体外和体内进行了全面的功能研究。

肝转移和腹膜转移在癌细胞及肿瘤微环境表型动态方面表现出不同的特性,支持了癌细胞与其局部肿瘤微环境在转移部位共同进化的观点。我们的研究还揭示了不同转移灶中癌症元程序的差异性激活。我们观察到在GAC进展过程中,癌细胞通过GPX4上调逃避铁死亡。条件性敲除Gpx4或药物抑制铁死亡抗性可显著减弱肿瘤生长和转移进展。此外,铁死亡再敏化治疗增强了CAR-T 细胞疗法的疗效。

展开英文摘要原文

BACKGROUND & AIMS: Metastases from gastric adenocarcinoma (GAC) lead to high morbidity and mortality. Developing innovative and effective therapies requires a comprehensive understanding of the tumor and immune biology of advanced GAC. Yet, collecting matched specimens from advanced, treatment-naïve patients with GAC poses a significant challenge, limiting the scope of current research, which has focused predominantly on localized tumors. This gap hinders deeper insight into the metastatic dynamics of GAC. METHODS: We performed in-depth single-cell transcriptome and immune profiling on 68 paired, treatment-naïve, primary metastatic tumors to delineate alterations in cancer cells and their tumor microenvironment during metastatic progression. To validate our observations, we conducted comprehensive functional studies both in vitro and in vivo, using cell lines and multiple patient-derived xenograft and novel mouse models of GAC. RESULTS: Liver and peritoneal metastases exhibited distinct properties in cancer cells and dynamics of tumor microenvironment phenotypes, supporting the notion that cancer cells and their local tumor microenvironments co-evolve at metastatic sites. Our study also revealed differential activation of cancer meta-programs across metastases. We observed evasion of cancer cell ferroptosis via GPX4 up-regulation during GAC progression. Conditional depletion of Gpx4 or pharmacologic inhibition of ferroptosis resistance significantly attenuated tumor growth and metastatic progression. In addition, ferroptosis-resensitizing treatments augmented the efficacy of chimeric antigen receptor T-cell therapy. CONCLUSIONS: This study represents the largest single-cell dataset of metastatic GACs to date. High-resolution mapping of the molecular and cellular dynamics of GAC metastasis has revealed a rationale for targeting ferroptosis defense in combination with chimeric antigen receptor T-cell therapy as a novel therapeutic strategy with potential immense clinical implications.

论文信息

作者
Cheng X、Dai E、Wu J、Flores NM、Chu Y、Wang R、Dang M、Xu Z
第一作者单位
Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China; Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.China
通讯作者单位
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas. Electronic address: LWang22@mdanderson.org.United States
期刊
Gastroenterology2024 Dec
原文标识
PubMed 39097198 · DOI 10.1053/j.gastro.2024.07.038